zoledronate

Zoledronate (also known as zoledronic acid) is a third-generation, nitrogen-containing bisphosphonate used to treat and prevent bone complications. It works by inhibiting osteoclast-mediated bone resorption, thereby increasing bone density and reducing the risk of fractures. Its mechanism involves binding to hydroxyapatite in bone and inhibiting farnesyl pyrophosphate synthase in the mevalonate pathway within osteoclasts, leading to impaired prenylation of small GTPase signaling proteins and ultimately inducing apoptosis in these cells. Zoledronate is primarily indicated for osteoporosis (in postmenopausal women, men, or those on glucocorticoids), Paget’s disease of bone, hypercalcemia of malignancy, multiple myeloma-related bone disease, and prevention/treatment of skeletal-related events from solid tumor metastases[2][3][4][5][7].

Brand names

ReclastZometaAclastaOrazol

Other names

zoledronic acid(1-hydroxy-2-imidazol-1-ylethylidene)diphosphonic acidphosphonic acid, [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis-Zoledronic Acid AnhydrousAnhydrous Zoledronic Acid